Core Insights - Fortress Biotech, Inc. has achieved significant milestones in 2025 and early 2026, including the FDA approval of ZYCUBO for Menkes disease and the sale of a Rare Pediatric Disease Priority Review Voucher for $205 million, demonstrating the company's ability to monetize its assets and advance its portfolio [2][5][12] Regulatory Updates - ZYCUBO (copper histidinate) received FDA approval in January 2026 for treating Menkes disease in pediatric patients [5] - The approval was followed by the sale of the Rare Pediatric Disease Priority Review Voucher by Cyprium Therapeutics for gross proceeds of $205 million [5] Monetization Updates - Checkpoint Therapeutics was acquired by Sun Pharma for approximately $355 million, with Fortress receiving about $28 million upfront and potential future payments including a 2.5% royalty on net sales of UNLOXCYT™ [4][6] - Fortress expects to receive at least $100 million from Cyprium through future dividends and intercompany agreements [5] Financial Performance - Fortress reported consolidated net revenue of $63.3 million for the full year ended December 31, 2025, an increase from $57.7 million in 2024 [12][20] - The company incurred a consolidated net loss attributable to common stockholders of $(1.9) million, or $(0.07) per share, for 2025, compared to a net loss of $(55.9) million, or $(2.69) per share, in 2024 [12][20] Clinical Updates - Crystalys Therapeutics announced a $205 million Series A financing to support Phase 3 clinical studies for dotinurad, with Fortress holding a 3% royalty on future net sales [9][10] - Emrosi™, developed by Journey Medical, reported net product revenues of $61.2 million for 2025, up from $55.1 million in 2024 [7][12]

Core Insights - Journey Medical Corporation reported total revenues of $61.9 million for FY2025, a 10% increase from $56.1 million in FY2024, primarily driven by the launch of Emrosi™ [5][15] - Emrosi™ generated net revenues of $14.7 million in its first year, with approximately 53,000 prescriptions filled [1][5] - The company achieved broader payer access for Emrosi™, now available to over 100 million U.S. commercial lives [1][10] Financial Performance - Gross margin improved to 66.2% in FY2025 from 62.8% in FY2024, attributed to higher-margin products like Emrosi™ and Qbrexza® [5] - Selling, general and administrative (SG&A) expenses rose to $44.4 million in FY2025, a 10% increase from $40.2 million in FY2024, mainly due to activities related to Emrosi™ [5] - The net loss for FY2025 was $11.4 million, or $(0.47) per share, compared to a net loss of $14.7 million, or $(0.72) per share in FY2024 [5][15] Adjusted Financial Metrics - Adjusted EBITDA for FY2025 was $2.9 million, or $0.12 per share basic, compared to $0.8 million, or $0.04 per share basic in FY2024 [5][19] - The company had cash and cash equivalents of approximately $24.1 million at the end of FY2025, up from $20.3 million at the end of FY2024 [5][14] Recent Corporate Highlights - Emrosi™ was launched commercially on April 7, 2025, following FDA approval in November 2024 [10] - Clinical trial results supporting Emrosi™'s efficacy were published in reputable journals, enhancing its market position [10] - The company is focused on leveraging its commercial platform to drive financial performance and advance innovative therapies for dermatological conditions [2]

Core Viewpoint - Fortress Biotech, Inc. and its subsidiary Cyprium Therapeutics announced the sale of a Rare Pediatric Disease Priority Review Voucher for $205 million, highlighting the company's strategic focus on value-generating transactions and advancements in their product pipeline [1][3]. Company Developments - Cyprium Therapeutics has transferred the development and commercialization rights of ZYCUBO to Sentynl Therapeutics, which was approved by the FDA on January 12, 2026, for treating Menkes disease [2]. - The PRV was issued following the FDA approval of ZYCUBO, and Cyprium is set to receive tiered royalties on net sales and up to $129 million in development and sales milestones from Sentynl [2]. - Cyprium is obligated to pay 20% of the PRV sale proceeds to the Eunice Kennedy Shriver National Institute of Child Health and Human Development [2]. Strategic Positioning - Fortress Biotech's Chairman emphasized the significance of the PRV sale and recent FDA approvals for their products, indicating a strong position to execute on their portfolio [3]. - Cyprium's recent achievements include the approval of ZYCUBO and the execution of the asset sale, with plans to advance AAV-ATP7A Gene Therapy for Menkes disease [3]. Company Background - Cyprium Therapeutics focuses on developing therapies for Menkes disease and related disorders, having established a partnership with the Eunice Kennedy Shriver National Institute of Child Health and Human Development for clinical development [4]. - Fortress Biotech is an innovative biopharmaceutical company with a diverse portfolio, including eight marketed products and multiple development programs across various therapeutic areas [5].

Core Insights - Journey Medical Corporation announced successful results from a Phase 1 clinical trial for Emrosi, indicating it can be safely used for up to 16 weeks without significant safety issues [1][2] - Emrosi is FDA-approved for treating inflammatory lesions of rosacea in adults, with a focus on maintaining normal microbiota and avoiding antibiotic resistance [2][5] Company Overview - Journey Medical Corporation is a commercial-stage pharmaceutical company focused on marketing FDA-approved prescription products for dermatological conditions [8] - The company currently markets eight branded FDA-approved prescription drugs aimed at treating common skin conditions [8] Clinical Trial Details - The Phase 1 clinical trial (DFD-29-CD-006) was a multicenter, randomized, double-blind, placebo-controlled study involving 60 healthy adults [2] - The trial achieved all primary microbiological endpoints, showing no significant changes in skin, gastrointestinal, or vaginal microbiota [5] - No significant safety issues were reported during the study, reinforcing the treatment's tolerability [2][5] Rosacea Background - Rosacea is a chronic inflammatory skin condition affecting over 16 million Americans and approximately 415 million people worldwide [3] - The condition significantly impacts patients' self-confidence and social interactions, with many reporting adverse effects on professional life [3]

Core Insights - Fortress Biotech reported a 20.5% increase in total net revenue, reaching $17.6 million for Q3 2025 compared to Q3 2024 [1] - The acquisition of Checkpoint Therapeutics by Sun Pharma resulted in Fortress receiving approximately $28 million at closing, with potential additional payments and royalties [1][2] - Dotinurad, a next-generation URAT1 inhibitor, is progressing in two Phase 3 clinical trials, supported by a $205 million Series A financing from Crystalys Therapeutics [1][2] Financial Performance - Fortress' consolidated net revenue for Q3 2025 was $17.6 million, up from $14.6 million in Q3 2024, with $17.0 million generated from dermatology products [11][19] - Consolidated net income attributable to common stockholders was $3.7 million, or $0.13 per share basic, compared to a net loss of $(15.0) million, or $(0.76) per share basic, in Q3 2024 [11][19] - Consolidated cash and cash equivalents increased to $86.2 million as of September 30, 2025, from $57.3 million at the end of 2024 [11] Corporate Developments - Fortress' Chairman highlighted strategic milestones, including the acquisition of Checkpoint and Baergic, reinforcing the company's diversified business model [2] - Journey Medical Corporation launched Emrosi™, achieving strong operational performance and expanded payer coverage, with net product revenues of $17.0 million in Q3 2025 [2][6] - The FDA issued a Complete Response Letter for CUTX-101, but the company plans to resubmit the NDA shortly [7] Clinical and Regulatory Updates - Dotinurad is advancing in two Phase 3 trials for gout treatment, with potential for best-in-class safety and efficacy [2][7] - Emrosi™ demonstrated statistical and clinical superiority over Oracea® and placebo for treating rosacea, as presented at the Fall Clinical Dermatology Conference [7] - The acquisition of Baergic by Axsome includes potential milestone payments and royalties, with Avenue Therapeutics eligible to receive approximately 74% of future payments [3]

Core Insights - Journey Medical Corporation reported third quarter 2025 net revenues of $17.6 million, a 21% increase year-over-year from $14.6 million in Q3 2024, driven by the commercial launch of Emrosi™ [3][6] - Emrosi™ total prescriptions surged by 146% compared to the second quarter of 2025, generating $4.9 million in net revenues for the third quarter [1][3] - The company anticipates significant operating leverage from the growth of Emrosi and its established dermatology commercial infrastructure [3] Financial Results - Gross margin improved to 67.4% in Q3 2025, compared to 69.4% in Q3 2024, influenced by higher revenues from Emrosi and Qbrexza, despite a favorable one-time adjustment in the previous year [6] - Selling, general and administrative (SG&A) expenses rose to $12.1 million in Q3 2025, a 6% increase from $11.4 million in Q3 2024, primarily due to operational activities related to Emrosi's launch [6] - The net loss for Q3 2025 was $2.3 million, slightly improved from a net loss of $2.4 million in Q3 2024, translating to $(0.09) per share [6][17] Recent Corporate Highlights - Emrosi's clinical differentiation was validated through a pooled Phase 3 efficacy analysis, showing statistically significant superiority over Oracea® and placebo [3][12] - The company expanded payer access for Emrosi to over 100 million commercial lives in the U.S. as of July 2025, up from 54 million in May 2025 [12] - Journey Medical's cash and cash equivalents increased to $24.9 million as of September 30, 2025, compared to $20.3 million at the end of 2024 [6]

Core Insights - Urica Therapeutics, a subsidiary of Fortress Biotech, has initiated Phase 3 trials for dotinurad, a new oral treatment for gout, marking a significant advancement in its clinical development program [1][3] Group 1: Clinical Trials - The RUBY study will evaluate dotinurad's safety and efficacy in approximately 500 patients with hyperuricemia associated with gout, with participants receiving the drug once daily for up to 64 weeks [4] - The TOPAZ study will assess dotinurad in about 250 patients with tophaceous gout, with a treatment duration of up to 76 weeks [5] Group 2: Market Context - Gout is a prevalent form of inflammatory arthritis caused by excess uric acid, leading to severe pain and inflammation, with a significant treatment gap for patients not responding to first-line therapies [6] - There are currently no suitable second-line treatment options available in the U.S. or E.U., highlighting a critical unmet need in the market [6] Group 3: Company Developments - Fortress Biotech has achieved significant milestones, including two FDA approvals and a substantial acquisition, enhancing its portfolio and potential revenue streams [3] - Urica holds a minority equity position in Crystalys and is entitled to a 3% royalty on future net sales of dotinurad, indicating a strategic financial interest in the drug's success [3]

Core Viewpoint - Urica Therapeutics, a subsidiary of Fortress Biotech, has initiated two Phase 3 clinical trials for dotinurad, a new oral treatment for gout, which could address significant unmet medical needs in this area [1][3]. Clinical Trials - The RUBY study will evaluate dotinurad's safety and efficacy in approximately 500 patients with hyperuricemia associated with gout, with participants receiving the drug once daily for up to 64 weeks [4]. - The TOPAZ study will assess dotinurad in about 250 patients with tophaceous gout, with a treatment duration of up to 76 weeks [5]. Company Developments - Fortress Biotech's Executive Chairman highlighted the initiation of these trials as a major milestone, building on recent successes including two FDA approvals and a significant acquisition [3]. - Fortress received approximately $28 million upfront from the acquisition of Checkpoint Therapeutics by Sun Pharma, with potential future payments and royalties [3]. Market Context - Gout is characterized by painful inflammation due to excess uric acid, and there is a notable treatment gap for patients who do not respond to first-line therapies [6]. - Current treatment options in the U.S. and E.U. are limited, indicating a critical need for new therapies like dotinurad [6]. Company Overview - Fortress Biotech focuses on acquiring and advancing biopharmaceutical assets to enhance shareholder value through various revenue streams [7]. - The company has a diverse portfolio, including eight marketed products and multiple development programs across therapeutic areas such as oncology and rare diseases [8].

Core Insights - Fortress Biotech, Inc. achieved significant milestones in Q2 2025, including the acquisition of its subsidiary Checkpoint Therapeutics by Sun Pharma, which provided approximately $28 million upfront and potential additional payments [2][3] - The FDA accepted the New Drug Application for CUTX-101 for Menkes disease, with a PDUFA goal date set for September 30, 2025 [2][6] - Journey Medical launched Emrosi™ for treating inflammatory lesions of rosacea, with commercial uptake expanding to cover 65% of U.S. commercial lives [2][5] Financial Performance - Fortress reported consolidated net revenue of $16.4 million for Q2 2025, an increase from $14.9 million in Q2 2024, primarily driven by dermatology product sales [11][18] - Consolidated cash and cash equivalents rose to $74.4 million as of June 30, 2025, up from $57.3 million at the end of 2024 [11][16] - The company recorded a net income attributable to common stockholders of $13.4 million, or $0.50 per share basic, compared to a net loss of $(13.3) million in the same quarter of the previous year [11][18] Regulatory Developments - The FDA granted Orphan Drug Designation to Mustang Bio for MB-101, enhancing the potential of the combination strategy with MB-108 for treating high-grade gliomas [6][12] - The NDA submission for CUTX-101 is under priority review, with expectations for a Priority Review Voucher upon approval [2][6] Commercial Updates - Journey Medical's Emrosi™ has seen expanded payer access, now covering over 100 million commercial lives in the U.S., up from 54 million in May 2025 [10][12] - The commercial launch of Emrosi™ began on April 7, 2025, following initial distribution and prescription filling [10][12] Corporate Developments - Fortress Biotech's subsidiary Journey Medical was added to the small-cap Russell 2000 Index and the broad-market Russell 3000 Index as of June 27, 2025 [8]

Core Insights - Journey Medical Corporation reported total revenues of $15.0 million for the second quarter of 2025, showing a slight increase from $14.9 million in the same quarter of the previous year [5] - Emrosi™ generated net sales of $2.8 million in its first full quarter on the market, indicating strong initial adoption and prescription ramp [2][5] - The company joined the Russell 2000® and Russell 3000® Indexes in June 2025, reflecting its growth and market presence [2][11] Financial Results - Total net product revenues for the second quarter of 2025 were $15.0 million, compared to $14.9 million in the prior year quarter [5] - Gross margin increased to 67% in Q2 2025 from 61% in Q2 2024, attributed to lower product costs and a favorable sales mix [5] - Selling, general and administrative expenses rose to $11.9 million in Q2 2025, up from $10.3 million in Q2 2024, primarily due to costs associated with the Emrosi launch [5] - The net loss for the second quarter was $3.8 million, or $(0.16) per share, compared to a net loss of $3.4 million, or $(0.17) per share, in the prior year [5][16] - At the end of Q2 2025, the company had $20.3 million in cash and cash equivalents, unchanged from December 31, 2024 [5] Recent Corporate Highlights - In July 2025, Journey Medical expanded payer access for Emrosi to over 100 million commercial lives in the U.S., up from 54 million in May 2025 [4] - The full commercial launch of Emrosi began on April 7, 2025, and has shown strong traction in the market [4] - Emrosi was featured in a segment on "The Balancing Act®" on Lifetime TV, highlighting treatment options for managing rosacea [11]